Celltrion Reports Positive Data For High-Concentration Adalimumab
Phase III Trials Cover Two Delivery Methods For CT-P17
• By Akriti Seth
Celltrion’s trials demonstrated the safety and efficacy of its high-concentration adalimumab biosimilar • Source: Shutterstock 
